Press release
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established method for the delivery of biopharmaceuticals.The Glutathione (GSH), a tripeptide formed from glutamic acid, cysteine and glycine, is active in many biological redox reactions. The conjugation of glutathione to its PEGylated liposome can be transported through the blood brain barrier in vivo via a sodium-dependent transporter. The GSH PEGylated liposomes enhance delivery of a fluorescent marker in the brain.
Biochempeg will PEGylate your peptide, or small molecule, and deliver your PEGylated product with a certificate of analysis, as a regular end-product, for further testing at your site. As a global partner, we can supply commercial quantities of high quality functionalized PEGs, which are essential for your PEGylated therapeutic proteins.
Pharmacological advantages of peptide PEGylation:
①Improved peptide solubility and enhanced protection from proteolytic degradation. The PEG polymer, along with its associated water molecules, acts like a shield to protect the attached peptide drug from enzyme degradation, thereby limiting adverse immunological effects. PEGylated peptides are more stable over a range of pH and temperature changes compared with their un-PEGylated counterparts.
②Reduced dosing frequency with potentially reduced toxicity. PEG exhibits little toxicity, and is eliminated intact from the body by either the kidneys (for PEGylated drugs 20 kDa).
③Increased peptide or drug stability and extended circulating life. PEG lacks immunogenicity, and antibodies against PEG in rabbits are generated only if it is combined with highly immunogenic proteins.
Biochempeg can attach the PEGs to peptides. Some examples are listed below:
①Monofunctional PEG Maleimide, Molecular Weight of 1K, 2K, 5K, 10K, 20K, or 30K
②Bifunctional Maleimide PEG Maleimide, Molecular Weight of 1K, 2K, 5K, 10K, 20K, or 30K
③DSPE-PEG-MAL, Maleimide functionalized PEG Lipid,Molecular Weight of 1K, 2K, or 5K
④Biotin PEG Maleimide, FITC, PEG Maleimide, Multi-arm-4/8 arm-PEG Maleimide
⑤Fmoc-ε-Ahx-OH, or N-ε-Fmoc-ε-aminocaproic acid; or Fmoc-6-aminohexanoic acid; CAS number: 88574-06-5; Molecular weight: 353.42 g/mol.
⑥Ahx or b-Ala can be used successfully as spacers during the generation of FITC-labeled peptides, which increases the stability of the fluorescent label. FITC can also be linked easily to a cysteine thiol moiety or to the amino group of lysine at any position.Synthesis using an Ahx linker in the lysine core resulted in better yields. Ahx increases the flexibility of peptide chains, which might help keep peptide chains properly solvated during synthesis, thereby preventing aggregation and increasing the amount of viable growing peptide sequences.
⑦{Mini-PEG}, 9 Carbons, CAS number: 166108-71-0; Fmoc-NH-(PEG)-COOH, or Fmoc-8-Amino-3,6-Dioxaoctanoic Acid; Molecular weight: 385.42 g/mol; C21H23NO6
⑧{Mini-PEG3}, Fmoc-AEEEA, CAS number: 139338-72-0; Fmoc-NH-(PEG)3-COOH, or Fmoc-11-Amino-3,6,9-Trioxaundecanoic Acid; Molecular weight: 429.47 g/mol; C23H27NO7
Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
Email: sales@biochempeg.com
Website: https://www.biochempeg.com
Biochempeg is dedicated to manufacturing and supplying high purity polyethylene glycol (PEG) derivatives and linkers, monodisperse PEG, ADC PEG linkers, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide. These PEG linkers have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, drug delivery and diagnostics field.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peptide Modifications For PEGylation here
News-ID: 2127059 • Views: …
More Releases from Biochempeg Scientific Inc.

Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…

Semaglutide VS Liraglutide: Which Is Better For Weight Loss
Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published in the Jan. 11 issue of the Journal of the American Medical Association.
Domenica M. Rubino, M.D., from the Washington Center for Weight Management and Research in Arlington, Virginia, and colleagues compared the efficacy and adverse event…

What Are Components And Mechanism Action of Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects tumor-specific proteins expressed on cancer cells and directs the cytotoxic anticancer drug towards the cancer cell.
Compared to alternative cancer treatments, for example, chemotherapy, immunotherapy, radiation, and stem cell therapy, ADC combines chemotherapy and immunotherapy and allows selective delivery of anticancer drugs and reduces systemic exposure and toxicity of anticancer drugs.
Components of ADC
One…

Sacituzumab govitecan shows promise in treating the most aggressive type of brea …
A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic triple-negative breast cancer. The study of the ADC drug sacituzumab govitecan (SG), for which Massachusetts General Hospital (MGH) was a lead clinical research site after serving as…
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By…
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm…
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due…
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition…
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in…
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…